

---

RESEARCHER

**Health Economics and HTA**

**MICHELA.MEREGAGLIA@UNIBOCCONI.IT**

---

## Biography

Michela Meregaglia is Researcher of Health Economics & HTA at the Government, Health and Not for Profit Knowledge Group at SDA Bocconi. She joined the Centre for Research on Health and Social Care Management (CERGAS), Health Economics & Health Technology Assessment (HTA) Area, in 2012. Since 2019, she is Contract Professor of "Pharmacy Management and Pharmacoeconomics" and "Pharmacoeconomics and Market Access" at the University of Eastern Piedmont, Department of Pharmaceutical Sciences.

Her main areas of research include economic evaluation of healthcare programmes, cost of illness analyses, health-related quality of life and health state utility estimation, preference elicitation methods in healthcare. She is author of several publications in the fields of health economics and health service research and reviewer for many international academic journals. Her manuscripts have been published in Value in Health, Pharmacoeconomics, the European Journal of Health Economics, International Journal of Technology Assessment in Health Care, Plos One, and Journal of Clinical Epidemiology, among others.

She has been involved in several national and international projects, such as the EU-funded BD4BO (2017-2019) promoting the development of value-based and outcomes-focused healthcare systems in Europe through the use of big data, and IMPACT-HTA (2018-2020) proposing new and improved methods, tools, and guidance for decision-makers in the context of HTA.

She holds a MSc in Economics and Management from Bocconi University, a 2nd level Master in Epidemiology and Biostatistics from Catholic University, and a PhD in Health Economics from the London School of Hygiene and Tropical Medicine (LSHTM). She is member of the International Health Economics Association (iHEA), the Italian Health Economics Association (AIES) and the Topics Board of the International Journal of Environmental Research and Public Health (IJERPH). She is married with a child.

## Teaching domains

Economic Evaluations of Drugs

Health Technology Assessment

Markov Models

Quality of Life

---

## ARTICLES IN SCHOLARLY JOURNALS

MEREGAGLIA M., MALANDRINI F., ANGELINI S., CIANI O.

**The Assessment of Patient-Reported Outcomes for the Authorisation of Medicines in Europe: A Review of European Public Assessment Reports from 2017 to 2022**

Applied Health Economics and Health Policy, 2023

- CIANI O., MEREGAGLIA M., BATTAGLIA M. A., BRICHETTO G., CONTE A., GASPERINI C., SANSONE V.  
**Patient-reported outcome measures in drugs for neurological conditions approved by European Medicines Agency 2017–2022**  
Neurological Sciences, 2023
- MEREGAGLIA M., MALANDRINI F., FINCH A. P., CIANI O., JOMMI C.  
**EQ-5D-5L Population Norms for Italy**  
Applied Health Economics and Health Policy, 2023, vol.21, no. 2, pp.289–303
- MALANDRINI F., BORRONI C., MEREGAGLIA M., SARRA M., CIANI O.  
**The role of patient-reported outcomes in reimbursement decisions and drug innovation in Italy**  
Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish, 2023, vol.10, no. 1, pp.12–17
- NICOD E., LLOYD A. J., MOREL T., MEREGAGLIA M., UPADHYAYA S., WHITTAL A., FACEY K., DRUMMOND M.  
**Improving Interpretation of Evidence Relating to Quality of Life in Health Technology Assessments of Rare Disease Treatments**  
The Patient, 2023, vol.16, no. 1, pp.7–17
- NICOD E., MEREGAGLIA M., WHITTAL A., UPADHYAYA S., FACEY K., DRUMMOND M.  
**Consideration of quality of life in the health technology assessments of rare disease treatments**  
The European Journal of Health Economics, 2022, vol.23, no. 4, pp.645–669
- MEREGAGLIA M., TARRICONE R.  
**Feasibility of Deriving Health State Utilities in Mycosis Fungoides Cutaneous T-Cell Lymphoma Using Mapping Algorithms**  
PharmacoEconomics – Open, 2022, vol.6, pp.595–603
- FINCH A. P., MEREGAGLIA M., CIANI O., ROUDIJK B., JOMMI C.  
**An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration**  
Social Science & Medicine, January, 2022, vol.292, pp.114519, 1–10
- CIANI O., SALCHER-KONRAD M., MEREGAGLIA M., SMITH K., GORST S. L., DODD S., WILLIAMSON P. R., FATTORE G.  
**Patient-Reported Outcome Measures in Core Outcome Sets targeted overlapping domains but through different instruments**  
Journal of Clinical Epidemiology, 5 March, 2021, vol.136, pp.26–36
- MEREGAGLIA M., NICOD E., DRUMMOND M.  
**The estimation of health state utility values in rare diseases: overview of existing techniques**  
International Journal of Technology Assessment in Health Care, 2020, vol.36, no. 5, pp.469–473
- MEREGAGLIA M., WHITTAL A., NICOD E., DRUMMOND M.  
**‘Mapping’ Health State Utility Values from Non-preference-Based Measures: A Systematic Literature Review in Rare Diseases**  
PharmacoEconomics, 2020, vol.38, no. 6, pp.557–574
- MEREGAGLIA M., BORSOI L., CAIRNS J., TARRICONE R.  
**Mapping health-related quality of life scores from FACT-G, FAACT, and FACIT-F onto preference-based EQ-5D-5L utilities in non-small cell lung cancer cachexia**  
The European Journal of Health Economics, 2019, vol.20, no. 2, pp.181–193
- MEREGAGLIA M., CAIRNS J., LICITRA L., BOSSI P.  
**The use of intensive radiological assessments in routine surveillance after treatment for head and neck cancer: An economic evaluation**  
European Journal of Cancer, 2018, vol.93, pp.89–98
- MEREGAGLIA M., CAIRNS J., ALFIERI S., FAVALES F., MAZZITELLI D., ORLANDI E., LICITRA L., BOSSI P.  
**Eliciting Preferences for Clinical Follow-Up in Patients with Head and Neck Cancer Using Best-Worst**

## Scaling

Value in Health, 2017, vol.20, no. 6, pp.799-808

CALLEA G., MEREGAGLIA M., TARRICONE R.

**Cost-effectiveness of reperfusion strategies for ST-elevation myocardial Infarction. Real-world data from the Stent For Life Initiative in Italy**

Value in Health, 2017, vol.20, no. 9, pp.PA592

MOZZI A., MEREGAGLIA M., LAZZARO C., TORNATORE V., BELFIGLIO M., FATTORE G.

**A comparison of EuroQol 5-Dimension health-related utilities using Italian, UK, and US preference weights in a patient sample**

ClinicoEconomics and Outcomes Research, 2016, vol.13, no. 8, pp.267-274

MEREGAGLIA M., TARRICONE R., ROGNONI C.

**Impatto economico dell'utilizzo di carbosimaltoso ferrico in pazienti con anemia da carenza di ferro nelle regioni italiane**

Mecosan, 2015, no. 93, pp.99-114

TIRANI M., MEREGAGLIA M., MELEGARO A.

**Health and Economic Outcomes of Introducing the New MenB Vaccine (Bexsero) into the Italian Routine Infant Immunisation Programme**

Plos One, 2015, vol.10, no. 4, pp.e0123383

---

## CONTRIBUTION TO CHAPTERS, BOOKS OR RESEARCH MONOGRAPHS

FATTORE G., MEDA F., MEREGAGLIA M.

**Gli Ospedali di Comunità: quali prospettive alla luce del PNRR?** in *Rapporto OASI 2022*

CERGAS (Eds),Egea, chap. 12, pp.465-517, 2022

ARDITO V., CIANI O., FEDERICI C. B., FURNARI A., FINCH A., JOMMI C., MALANDRINI F., MEREGAGLIA M., TARRICONE R.

**Esiti di salute e performance del Servizio Sanitario Nazionale** in *Rapporto OASI 2021*

Cergas (Eds),Egea, chap. 7, pp.303-359, 2021

FATTORE G., MEDA F., MEREGAGLIA M.

**Gli Ospedali di Comunità in Italia: passato, presente e futuro** in *Rapporto OASI 2021*

CERGAS (Eds),Egea, chap. 14, pp.563-601, 2021

---

## OTHER IN JOURNALS

CIANI O., MEREGAGLIA M., DE LORENZO F., PERRONE F., PINTO C.

**Patient-Reported Outcome Measures in Oncology Drugs Approved by the European Medicines Agency, 2017-2021**

2023, JAMA Network Open

ARMENI P., MEREGAGLIA M., BORSOI L., TORBICA A., CALLEA G.

**PMD16 What Factors Do Clinicians Value Most in Selecting Physician Preference Items? a Survey in Orthopedics Using Discrete Choice Experiment and Best-Worst Scaling**

2021, Value in Health

---

## PROCEEDINGS/PRESENTATIONS

ARMENI P., MEREGAGLIA M., BORSOI L., CALLEA G., TORBICA A., TARRICONE R.

**Are physicians aware about their preferences when choosing a technology? Evidence from Italian orthopaedists using two different stated preference methods**

*Italian Health Economics Association (AIES), 26th Annual Conference, 2-3 December, 2021, Milano, Italy*

MEREGAGLIA M., FINCH A. P., CIANI O., JOMMI C.

**EQ-5D-5L population norms for Italy**

*Italian Health Economics Association (AIES), 26th Annual Conference, 2-3 December, 2021, Milano, Italy*

FATTORE G., MEDA F., MEREGAGLIA M.

**Gli ospedali di comunità in Italia: passato, presente e futuro**

*Italian Health Economics Association (AIES), 26th Annual Conference, 2-3 December, 2021, Milano, Italy*

MEREGAGLIA M., D'AGOSTINO P., TURINI M., TARRICONE R.

**Deriving health state utility values in mycosis fungoides cutaneous T-cell lymphoma using mapping algorithms**

*EUHEA Conference (virtual), 9 July, 2020, Oslo, Norway*

MEREGAGLIA M., WHITTAL A., NICOD E., DRUMMOND M.

**Predicting Health Utilities from Patient-Reported Outcome Measures (Proms) in Rare Diseases: A Systematic Review of 'Mapping' Studies**

*AIES (Italian Health Economics Association), 24th Annual Conference, 3-4 October, 2019, Pisa, Italy*

CALLEA G., MEREGAGLIA M., TARRICONE R.

**Cost-effectiveness of reperfusion strategies for ST-elevation myocardial Infarction. Real-world data from the Stent For Life Initiative in Italy**

*ISPOR Europe Conference -November 4-8, 2017, Glasgow, Great Britain*

---

## RESEARCH NOTES OR SHORT ARTICLES IN JOURNALS

MEREGAGLIA M., FERRARA L., MELEGARO A., DEMICHELI V.

**Parent "cocoon" immunization to prevent pertussis-related hospitalization in infants: The case of Piemonte in Italy**

2013, *Vaccine*

---